Serdexmethylphenidate/Dexmethylphenidate Improves Sleep in Children With ADHD

Serdexmethylphenidate/dexmethylphenidate improved sleep scores in children with attention-deficit/hyperactivity disorder.

Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) has been shown to improve sleep measures among children with attention-deficit/hyperactivity disorder (ADHD), according to study results presented at Psych Congress 2022 held from September 17 to 20, 2022, in New Orleans, Louisiana.

Researchers conducted a 1-year, dose-optimized, open-label study to evaluate the effect of SDX/d-MPH on sleep. A total of 282 children aged 6 to 12 years with ADHD were included in the study. Patients who were naive to SDX/d-MPH received 39.2/7.8 mg SDX/d-MPH for 7 days optimized to 52.3/10.4 mg SDX/d-MPH. The primary outcome was change in Children’s Sleep Habits Questionnaire (CSHQ) scores. A sleep disorder was defined as CSHQ score of at least 41.

Patient population comprised 60.9% boys with a mean age of 9.1 (SD, 1.87) years. Of the study patients, 47.5% were White, 46.6% were Black, and BMI was 19.3 (SD, 4.6) kg/m2, respectively.

At baseline, the average CSHQ total score was 53.4 (SD, 5.9). After 1 month of SDX/d-MPH treatment, scores had decreased by 2.9 points to 50.5 (P <.0001), remaining between 48.9 and 50.1 points through month 12.

In this study of children taking SDX/d-MPH for ADHD, statistically significant improvements in most CSHQ sleep domains were observed after [1] month and lasted for up to 12 months of treatment.

Stratified by CSHQ sleep domains, significant decreases were observed for the following:

  • Daytime sleepiness (least squares mean difference [LSMD], -2.0; P <.0001);
  • Parasomnias (LSMD, -1.1; P <.0001);
  • Sleep anxiety (LSMD, -0.9; P <.0001);
  • Bedtime resistance (LSMD, -0.7; P <.0001);
  • Night wakings (LSMD, -0.5; P <.0001);
  • Sleep-disordered breathing (LSMD, -0.1; P =.0111)

Compared with baseline, there were increases to sleep onset (LSMD, 0.4; P <.0001) and sleep duration (LSMD, 0.2; P =.0091) subscores.

A potential limitation of this study is that some children (n=70) were pre-exposed to SDX/d-MPH as they were recruited from a previous trial.

Study authors conclude, “In this study of children taking SDX/d-MPH for ADHD, statistically significant improvements in most CSHQ sleep domains were observed after [1] month and lasted for up to 12 months of treatment. Importantly, the use of SDX/d-MPH did not worsen sleep problems.”

Disclosure: Multiple authors declared affiliations with industry. Please refer to the original article for a full list of disclosures.

References:

Mattingly GW, Childress AC, Cutler AJ, et al. Serdexmethylphenidate/Dexmethylphenidate effects on sleep in children with attention-deficit hyperactivity disorder. Abstract presented at Psych Congress 2022; September 17-20, 2022. Poster 52.